Subcutaneous Injections – Talk Bio

Actionable Insights Powered by AI

FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE

3 weeks ago talkbio0Tagged Andembry, Angioedemas, Hereditary, Approved, dosing, factor XIIa, garadacimab-gxii, Inhibitor, SMPX gene, Subcutaneous Injections, Takeda, Takhzyro, United States Food and Drug Administration

Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection

FDA Approves Ocrevus Zunovo: A Breakthrough Subcutaneous Injection for Multiple Sclerosis

10 months ago talkbio0Tagged Approved, drug delivery technology, ENHANZE, Halozyme, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Ocrevus Zunovo, PPMS, Progressive, Relapsing Multiple Sclerosis, RMS, Subcutaneous Injections, United States Food and Drug Administration

Ocrevus Zunovo, FDA Approval, Subcutaneous Injection, Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS), Halozyme Therapeutics, ENHANZE drug delivery technology.